Evaluation of the risk of nitrosamine impurities

Communication Marketing
Regulatory affairs Pharmaceutical industry
Regulatory affairs Pharmaceutical industry
May 6, 2020
  • Drug Development
image_pdfPDF

“During the summer 2018, authorities become aware of the presence of some nitrosamines in API – (Valsartan – presence of N- nitrosodimethylamine (NDMA) – other sartans – presence of N-nitrosodiethylamine NDEA).   These nitrosamines were already known as probable carcinogenic compounds but their presence in the sartans was not then identified.”

 

To read the whole document, please download the white paper.

Register to download the White paper

    By sending this form, I agree that my personal data will be saved and processed according to data protection regulations and will be used only for commercial and marketing purposes only.

    Learn more


    BlueReg undertakes to comply with the regulations in force applicable to the processing of personal data and, in particular, Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 applicable as from 25 May 2018 (hereinafter, "the General Data Protection Regulations" or GPDR) and the national laws resulting therefrom.
    Any inquiries, correction or declaration of event related to personal data processed should be sent to: GDPR data request

    GDPR data request

    Thank you for your interest in BlueReg.


    The file will be sent to you by email.

    Download your White paper